IR@PKUHSC  > 北京大学第一临床医学院  > 泌尿外科
学科主题临床医学
The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy
Yu, Xiaoteng1; Wang, Bing2; Li, Xuesong1; Lin, Gang3; Zhang, Cuijian1; Yang, Yang1; Fang, Dong1; Song, Yi1; He, Zhisong1; Zhou, Liqun1
刊名BIOMED RESEARCH INTERNATIONAL
2015
DOI10.1155/2015/176373
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biotechnology & Applied Microbiology ; Medicine, Research & Experimental
研究领域[WOS]Biotechnology & Applied Microbiology ; Research & Experimental Medicine
关键词[WOS]PROGNOSTIC-FACTORS ; SURVIVAL ; CANCER ; NEPHRECTOMY ; RESECTION ; TUMORS ; TRIAL
英文摘要

Objective. To investigate the efficacy of surgery in the treatment of metastatic renal cell carcinoma (mRCC) and to identify prognostic factors. Methods. A single center retrospective study of 96 patients with mRCC from December 2004 to August 2013. Results. The median follow-up time was 45 months. Thirty-one (32.3%) of the patients received complete resection of metastatic sites, 11 (11.5%) of the patients underwent incomplete resection of metastatic sites, and 54 (56.3%) of the patients received no surgery. In the univariate Kaplan-Meier analysis, the median overall survival times of the three groups were 52 months, 16 months, and 22 months, respectively (p < 0.001). The difference in the overall survival time was statistically significant between complete resection and no surgery groups (HR = 0.43, p = 0.009), while there was no significant difference between the incomplete metastasectomy and no surgery groups (HR = 1.80, p = 0.102). According to the multivariate Cox regression analysis, complete metastasectomy (HR = 0.49, p = 0.033), T stage > 3 (HR = 1.88, p = 0.015), disease free interval <12 months (HR = 2.34, p = 0.003), and multiorgan involvement (HR = 2.00, p = 0.011) were significant prognostic factors. Conclusion. In the era of targeted therapy, complete metastasectomy can improve overall survival. Complete metastasectomy, T stage > 3, disease free interval <12 months, and multiorgan involvement are independent prognostic factors.

语种英语
WOS记录号WOS:000363563300001
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/67909
专题北京大学第一临床医学院_泌尿外科
北京大学第一临床医学院_胸外科
作者单位1.Peking Univ, Natl Urol Canc Ctr, Hosp 1, Inst Urol,Dept Urol, Beijing 100034, Peoples R China
2.Peking Univ, Dept Orthoped, Hosp 1, Beijing 100034, Peoples R China
3.Peking Univ, Hosp 1, Dept Thorac Surg, Beijing 100034, Peoples R China
推荐引用方式
GB/T 7714
Yu, Xiaoteng,Wang, Bing,Li, Xuesong,et al. The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy[J]. BIOMED RESEARCH INTERNATIONAL,2015.
APA Yu, Xiaoteng.,Wang, Bing.,Li, Xuesong.,Lin, Gang.,Zhang, Cuijian.,...&Zhou, Liqun.(2015).The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy.BIOMED RESEARCH INTERNATIONAL.
MLA Yu, Xiaoteng,et al."The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy".BIOMED RESEARCH INTERNATIONAL (2015).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yu, Xiaoteng]的文章
[Wang, Bing]的文章
[Li, Xuesong]的文章
百度学术
百度学术中相似的文章
[Yu, Xiaoteng]的文章
[Wang, Bing]的文章
[Li, Xuesong]的文章
必应学术
必应学术中相似的文章
[Yu, Xiaoteng]的文章
[Wang, Bing]的文章
[Li, Xuesong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。